Zacks Investment Research downgraded shares of MALLINCKRODT PL (MNK) from NEUTRAL to UNDERPERFORM on September 03, 2013, with a target price of $41.70.
Mallinckrodt Plc. is engaged in pharmaceuticals business. It develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company's Specialty Pharmaceuticals segment includes branded and generic drugs and Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt Plc. is based in Dublin, Ireland.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on MALLINCKRODT PL (MNK),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment